Compare Expeditors International of Wshngtn Inc (EXPD) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expeditors International of Wshngtn Inc vs Zimmer Biomet Holdings Inc — how do they compare? Expeditors International of Wshngtn Inc trades at $193.74 (market cap $24.81B), while Zimmer Biomet Holdings Inc trades at $88.9 (market cap $16.88B). The key difference: Expeditors International of Wshngtn Inc is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (1.08%). Which is the better fit depends on your goals — on Pluang, investors hold Expeditors International of Wshngtn Inc for 43 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| EXPD | ZBH | |
|---|---|---|
Market Cap | $24.81B | $16.88B |
Volume | 832,787 | 1,991,354 |
Sector | Industrials | Health |
52-Week High | $194.12 | $103.98 |
52-Week Low | $113.13 | $79.58 |
Typical Hold Time | 43 Days | 89 Days |
Enterprise Value | $24.34B | $23.95B |
Dividend Yield | 0.85% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXPD trades at $193.71, up 1.0% with a bullish technical signal supported by moving averages. The company demonstrates strong profitability with 42.6% ROE and has beaten earnings estimates for three consecutive quarters. Recent news highlights efficiency initiatives and resilient airfreight demand as positive catalysts. Institutional activity shows mixed positioning with some major funds increasing stakes while others reduced exposure.
While EXPD shows strong operational metrics and earnings momentum, the stock trades above analyst consensus target of $174.86, suggesting limited near-term upside. Risks include competitive pressures and potential freight market volatility. The company's focus on efficiency and shareholder returns provides stability, but valuation remains elevated at 27.78 P/E ratio.
Zimmer Biomet (ZBH) trades at $88.91, down 0.86% on the day, with a bearish technical signal from moving averages. The company reported revenue of $8.23B in 2025, with net income of $705.1M, and has beaten EPS estimates for the last three quarters. Recent news highlights a quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The outlook is mixed: strong fundamentals and consistent earnings beats support growth, but technical indicators and rising debt-to-asset ratios pose risks. Analyst consensus suggests a 16% upside to the $103.11 price target, though nearly half of analysts recommend Hold. Key risks include competitive pressures and execution of the company's strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
